Papers

Assessing possible hazards of reducing serum cholesterol

Department of Environmental and Preventive Medicine, Wolfson Institute of Preventive Medicine, St Bartholomew's Medical College, London EC1M 6BQ Correspondence to: Dr Law.

Abstract

Objective : To assess whether low serum cholesterol concentration increases mortality from any cause. Design - Systematic review of published data on mortality from causes other than ischaemic heart disease derived from the 10 largest cohort studies, two international studies, and 28 randomised trials, supplemented by unpublished data on causes of death obtained when necessary.
Main outcome measures : Excess cause specific mortality associated with low or lowered serum cholesterol concentration.
Results : The only cause of death attributable to low serum cholesterol concentration was haemorrhagic stroke. The excess risk was associated only with concentrations below about 5 mmol/l (relative risk 1.9, 95% confidence interval 1.4 to 2.5), affecting about 6% of people in Western populations. For non-circulatory causes of death there was a pronounced difference between cohort studies of employed men, likely to be healthy at recruitment, and cohort studies of subjects in community settings, necessarily including some with existing disease. The employed cohorts showed no excess mortality. The community cohorts showed associations between low cholesterol concentration and lung cancer, haemopoietic cancers, suicide, chronic bronchitis, and chronic liver and bowel diseases; these were most satisfactorily explained by early disease or by factors that cause the disease lowering serum cholesterol concentration (depression causes suicide and lowers cholesterol concentration, for example). In the randomised trials nine deaths (from a total of 687 deaths not due to ischaemic heart disease in treated subjects) were attributed to known adverse effects of the specific treatments, but otherwise there was no evidence of an increased mortality from any cause arising from reduction in cholesterol concentration.
Conclusions : There is no evidence that low or reduced serum cholesterol concentration increases mortality from any cause other than haemorrhagic stroke. This risk affects only those people with a very low concentration and even in these will be outweighed by the benefits from the low risk of ischaemic heart disease.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    StumbleUpon    Technorati    What's this?

Relevant Articles

Risk factor thresholds

Michael A Soljak, Malcolm E Kendrick, Steven M Laitner, Malcolm Law, and Nicholas J Wald
BMJ 2002 325: 1114. [Extract] [Full Text]

Hazards of reducing cholesterol

C Lines
BMJ 1994 309: 541. [Extract] [Full Text]

This article has been cited by other articles:

• Thompson, G. R. (2009). History of the cholesterol controversy in Britain. QJM 102: 81-86 [Abstract] [Full text]  
• Steinberg, D. (2008). Statin Treatment Does Not Cause Cancer. J Am Coll Cardiol 52: 1148-1149 [Full text]  
• Woodward, M., Barzi, F., Feigin, V., Gu, D., Huxley, R., Nakamura, K., Patel, A., Ho, S., Jamrozik, K., for the Asia Pacific Cohort Studies Collaboration, (2007). Associations between high-density lipoprotein cholesterol and both stroke and coronary heart disease in the Asia Pacific region. Eur Heart J 28: 2653-2660 [Abstract] [Full text]  
• Shor, R., Wainstein, J., Oz, D., Boaz, M., Matas, Z., Fux, A., Halabe, A. (2007). Low Serum LDL Cholesterol Levels and the Risk of Fever, Sepsis, and Malignancy. Annals of Clinical & Laboratory Science 37: 343-348 [Abstract] [Full text]  
• Hindler, K., Cleeland, C. S., Rivera, E., Collard, C. D. (2006). The Role of Statins in Cancer Therapy.. The Oncologist 11: 306-315 [Abstract] [Full text]  
• Vogel, V. G. (2005). Can Statin Therapy Reduce the Risk of Breast Cancer?. JCO 23: 8553-8555 [Full text]  
• Roquer, J., Campello, A. R., Gomis, M., Ois, A., Munteis, E., Bohm, P. (2005). Serum lipid levels and in-hospital mortality in patients with intracerebral hemorrhage. Neurology 65: 1198-1202 [Abstract] [Full text]  
• Golomb, B. A., Criqui, M. H., White, H., Dimsdale, J. E. (2004). Conceptual Foundations of the UCSD Statin Study: A Randomized Controlled Trial Assessing the Impact of Statins on Cognition, Behavior, and Biochemistry. Arch Intern Med 164: 153-162 [Abstract] [Full text]  
• Yang, C.-C., Jick, S. S., Jick, H. (2003). Lipid-Lowering Drugs and the Risk of Depression and Suicidal Behavior. Arch Intern Med 163: 1926-1932 [Abstract] [Full text]  
• Weverling-Rijnsburger, A. W. E., Jonkers, I. J. A. M., van Exel, E., Gussekloo, J., Westendorp, R. G. J. (2003). High-Density vs Low-Density Lipoprotein Cholesterol as the Risk Factor for Coronary Artery Disease and Stroke in Old Age. Arch Intern Med 163: 1549-1554 [Abstract] [Full text]  
• Law, M R, Wald, N J, Rudnicka, A R (2003). Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 326: 1423- [Abstract] [Full text]  
• Chan, K. K. W., Oza, A. M., Siu, L. L. (2003). The Statins as Anticancer Agents. Clin. Cancer Res. 9: 10-19 [Abstract] [Full text]  
• (2002). References. Circulation 106: 3373-3421 [Full text]  
• Di Napoli, P., Taccardi, A.A., Oliver, M., De Caterina, R. (2002). Statins and stroke: evidence for cholesterol-independent effects. Eur Heart J 23: 1908-1921  
• Soljak, M. A, Kendrick, M. E, Laitner, S. M, Law, M., Wald, N. J (2002). Risk factor thresholds. BMJ 325: 1114-1114 [Full text]  
• Llewellyn-Thomas, H. A., Paterson, J. M., Carter, J. A., Basinski, A., Myers, M. G., Hardacre, G. D., Dunn, E. V., D'Agostino, R. B., Wolf, P. A., Naylor, C. D. (2002). Primary Prevention Drug Therapy: Can It Meet Patients' Requirements for Reduced Risk?. Med Decis Making 22: 326-339 [Abstract]  
• Cui, Y., Blumenthal, R. S., Flaws, J. A., Whiteman, M. K., Langenberg, P., Bachorik, P. S., Bush, T. L. (2001). Non-High-Density Lipoprotein Cholesterol Level as a Predictor of Cardiovascular Disease Mortality. Arch Intern Med 161: 1413-1419 [Abstract] [Full text]  
• Kiss, A., Ortiz-Aguayo, R., Sharp, R., Merlino, G., Thorgeirsson, S. S., Gonzalez, F. J., Peters, J. M. (2001). Evidence that reduction of hepatocyte growth factor (HGF) is not required for peroxisome proliferator-induced hepatocyte proliferation. Carcinogenesis 22: 975-979 [Abstract] [Full text]  
• Palmer, C. J. Jr. (2001). African Americans, Depression, and Suicide Risk. Journal of Black Psychology 27: 100-111 [Abstract]  
• Stewart, R. A., Sharples, K. J., North, F. M., Menkes, D. B., Baker, J., Simes, J., for the LIPID Study Investigators, (2000). Long-term Assessment of Psychological Well-being in a Randomized Placebo-Controlled Trial of Cholesterol Reduction With Pravastatin. Arch Intern Med 160: 3144-3152 [Abstract] [Full text]  
• Law, M. (2000). Dietary fat and adult diseases and the implications for childhood nutrition: an epidemiologic approach. Am. J. Clin. Nutr. 72 : 1291S-1296S [Abstract] [Full text]  
• Blais, L., Desgagne, A., LeLorier, J. (2000). 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors and the Risk of Cancer: A Nested Case-Control Study. Arch Intern Med 160: 2363-2368 [Abstract] [Full text]  
• GARLAND, M., HICKEY, D., CORVIN, A., GOLDEN, J., FITZPATRICK, P., CUNNINGHAM, S., WALSH, N. (2000). Total serum cholesterol in relation to psychological correlates in parasuicide. Br. J. Psychiatry 177: 77-83 [Abstract] [Full text]  
• Vauthey, C., de Freitas, G. R., van Melle, G., Devuyst, G., Bogousslavsky, J. (2000). Better outcome after stroke with higher serum cholesterol levels. Neurology 54: 1944-1949 [Abstract] [Full text]  
• McCreary, A. C., Handley, S. L. (2000). Chronic administration of the cholesterol reducing drug gemfibrozil fails to alter 5-HT1A and 5-HT2A mediated receptor behaviours in rats. J Psychopharmacol 14: 280-283 [Abstract]  
• Marshall, T., Kennedy, E., Offutt, S. (2000). Exploring a fiscal food policy: the case of diet and ischaemic heart disease • Commentary: Alternative nutrition outcomes using a fiscal food policy. BMJ 320: 301-305 [Full text]  
• Rossouw, J. E. (1999). Does Estrogen Have a Role in the Prevention of Cardiovascular Disease?. J. Clin. Endocrinol. Metab. 84: 1806-1810 [Full text]  
• Bucher, H. C., Griffith, L. E., Guyatt, G. H. (1999). Systematic Review on the Risk and Benefit of Different Cholesterol-Lowering Interventions. Arterioscler. Thromb. Vasc. Bio. 19: 187-195 [Abstract] [Full text]  
• British Cardiac Society, , British Hyperlipidaemia Association, , British Hypertension Society, , endorsed by the British Diabetic Association, (1998). Joint British recommendations on prevention of coronary heart disease in clinical practice. Heart 80: 1S-29 [Full text]  
• Hippisley-Cox, J., Fielding, K., Pringle, M. (1998). Depression as a risk factor for ischaemic heart disease in men: population based case-control study. BMJ 316: 1714-1719 [Abstract] [Full text]  
• Borgia, M. C., Medici, F. (1998). Perspectives in the Treatment of Dyslipidemias in the Prevention of Coronary Heart Disease. ANGIOLOGY 49: 339-348 [Abstract]  
• Jousilahti, P., Vartiainen, E., Pekkanen, J., Tuomilehto, J., Sundvall, J., Puska, P. (1998). Serum Cholesterol Distribution and Coronary Heart Disease Risk : Observations and Predictions Among Middle-aged Population in Eastern Finland. Circulation 97: 1087-1094 [Abstract] [Full text]  
• Gould, A. L., Rossouw, J. E., Santanello, N. C., Heyse, J. F., Furberg, C. D. (1998). Cholesterol Reduction Yields Clinical Benefit : Impact of Statin Trials. Circulation 97: 946-952 [Abstract] [Full text]  
• Cullen, P., Schulte, H., Assmann, G. (1997). The Munster Heart Study (PROCAM) : Total Mortality in Middle-Aged Men Is Increased at Low Total and LDL Cholesterol Concentrations in Smokers but Not in Nonsmokers. Circulation 96: 2128-2136 [Abstract] [Full text]  
• Raiha, I., Marniemi, J., Puukka, P., Toikka, T., Ehnholm, C., Sourander, L. (1997). Effect of Serum Lipids, Lipoproteins, and Apolipoproteins on Vascular and Nonvascular Mortality in the Elderly. Arterioscler. Thromb. Vasc. Bio. 17: 1224-1232 [Abstract] [Full text]  
• Manton, K. G., Corder, L., Stallard, E. (1997). Chronic disability trends in elderly United States populations: 1982-1994. Proc. Natl. Acad. Sci. USA 94: 2593-2598 [Abstract] [Full text]  
• Keyserling, T. C., Ammerman, A. S., Davis, C. E., Mok, M. C., Garrett, J., Simpson, R. Jr (1997). A Randomized Controlled Trial of a Physician-Directed Treatment Program for Low-Income Patients With High Blood Cholesterol: The Southeast Cholesterol Project. Arch Fam Med 6: 135-145 [Abstract]  
• Rossouw, J. E. (1996). Estrogens for Prevention of Coronary Heart Disease: Putting the Brakes on the Bandwagon. Circulation 94: 2982-2985 [Full text]  
• Zureik, M., Courbon, D., Ducimetiere, P. (1996). Serum cholesterol concentration and death from suicide in men: Paris prospective study I. BMJ 313: 649-651 [Abstract] [Full text]  
• Law, M. (1996). Commentary: Having too much evidence (depression, suicide, and low serum cholesterol). BMJ 313: 651-652 [Full text]  
• Marchioli, R., Marfisi, R. M., Carinci, F., Tognoni, G. (1996). Meta-analysis, Clinical Trials, and Transferability of Research Results Into Practice: The Case of Cholesterol-Lowering Interventions in the Secondary Prevention of Coronary Heart Disease. Arch Intern Med 156: 1158-1172 [Abstract]  
• Newman, T. B., Hulley, S. B. (1996). Carcinogenicity of Lipid-Lowering Drugs. JAMA 275: 55-60 [Abstract]  
• Dalen, J. E., Dalton, W. S. (1996). Does Lowering Cholesterol Cause Cancer?. JAMA 275: 67-69 [Abstract]  
• Zureik, M., Ducimetiere, P., Warnet, J.-M., Orssaud, G. (1995). Fatty acid proportions in cholesterol esters and risk of premature death from cancer in middle aged French men. BMJ 311: 1251-1254 [Abstract] [Full text]  
• Meilahn, E. N. (1995). Low Serum Cholesterol : Hazardous to Health?. Circulation 92: 2365-2366 [Full text]  
• Iribarren, C., Reed, D. M., Chen, R., Yano, K., Dwyer, J. H. (1995). Low Serum Cholesterol and Mortality : Which Is the Cause and Which Is the Effect?. Circulation 92: 2396-2403 [Abstract] [Full text]  
• Law, M R, Wald, N J (1995). Serum cholesterol concentrations in parasuicide. BMJ 311: 807a-807 [Full text]  
• Clarke, A. (1995). Population screening for genetic susceptibility to disease. BMJ 311: 35-38 [Full text]  
• Gallerani, M., Manfredini, R., Caaracciolo, S., Scapoli, C., Molinari, S., Fersini, C. (1995). Serum cholesterol concentraions in parasuicide. BMJ 310: 1632-1639 [Abstract] [Full text]  
• Havel, R. J., Rapaport, E. (1995). Management of Primary Hyperlipidemia. NEJM 332: 1491-1498 [Full text]  
• Gould, A. L., Rossouw, J. E., Santanello, N. C., Heyse, J. F., Furberg, C. D. (1995). Cholesterol Reduction Yields Clinical Benefit : A New Look at Old Data. Circulation 91: 2274-2282 [Abstract] [Full text]  
• Oxman, A. D., Cook, D. J., Guyatt, G. H., the Evidence-Based Medicine Working Group, , Bass, E., Brill-Edwards, P., Browman, G., Detsky, A., Farkouh, M., Gerstein, H., Haines, T., Haynes, B., Hayward, R., Holbrook, A., Jaeschke, R., Juniper, E., Laupacis, A., Lee, H., Levine, M., Moyer, V., Naylor, D., Nishikawa, J., Patel, A., Philbrick, J., Richardson, S., Sauve, S., Sacked, D., Sinclair, J., Strom, B., Trout, K. S., Tunis, S., Walter, S., Williams, J. Jr, Wilson, M. (1994). Users' Guides to the Medical Literature: VI. How to Use an Overview. JAMA 272: 1367-1371 [Abstract]  
• Lines, C (1994). Hazards of reducing cholesterol. BMJ 309: 541-541 [Full text]  
• Ryman, A (1994). Cholesterol, violent death, and mental disorder. BMJ 309: 421-2 [Full text]  
• Variainen, E, Puska, P, Pekkanen, J, Tuomilehto, J, Lonnqvist, J, Ehnholm, C (1994). Serum cholesterol concentration and mortality from accidents, suicide, and other violent causes. BMJ 309: 445-7 [Abstract] [Full text]  
• Weetman, D.F., Munby, J. (1994). Categories of Adverse Health Effects from Indoor Air Pollution. Indoor and Built Environment 3: 200-212 [Abstract]  
• Bhopal, R. S., Tonks, A. (1994). The role of letters in reviewing research. BMJ 308: 1582-1583 [Full text]  
• Muldoon, M F, Manuck, S B, Law, M R, Wald, N J, Wu, T, Hackshaw, A, Thompson, S G, Bailey, A (1994). Ischaemic heart disease and cholesterol Safety of cholesterol reduction remains in doubt. BMJ 308: 1104-1105 [Full text]  
• Smith, G D, Egger, M (1994). Commentary: Statistical problems. BMJ 308: 1025-1027 [Full text]  
• Law, M R, Wald, N J (1994). Commentary: Disagreements are not substantial. BMJ 308: 1027-1029 [Full text]  
• Bonneux, L, Barendregt, J J, Ravnskov, U, Ramsay, L E, Yeo, W W, Jackson, P R, Sheldon, T A, Song, F, Millo, J, Sudlow, C L M, Macleod, M R, Heady, J A, Morris, J N, Oliver, M F, Vine, D L, Hastings, G E, Durrington, P N, Dugdale, A, Law, M R, Wu, T, Wald, N J, Hackshaw, A, Bailey, A S G T. (1994). Ischaemic heart disease and cholesterol There's more to heart disease than cholesterol. BMJ 308: 1038-1041 [Full text]  
• (1994). REASSESSING THE HAZARDS OF CHOLESTEROL REDUCTION. JWatch General 1994: 5-5 [Full text]  
• Marmot, M (1994). The cholesterol papers. BMJ 308: 351-352 [Full text]